Notice
Combination therapies: prioritisation statement
Under some circumstances (clarified in this statement), the CMA will not prioritise enforcement action against competing drug firms in relation to commercial negotiations to make combination therapies available to patients, through the NHS.
Documents
Details
In this statement, the Competition and Markets Authority (CMA) clarifies the circumstances under which it will not prioritise enforcement action against drug firms when they implement a specific ‘negotiation framework’ to make more combination therapies available on the NHS.
The CMA’s statement applies only where certain market features are present and particular conditions are met.
Combination therapies are treatments using 2 or more medicines in combination.
Published 17 November 2023